IGEA Pharma N.V. reports earnings results for first half 2021. The Group did not generate revenue during the first six months of 2021 against previous period revenue of USD 46,800. The net loss for the period is USD 291,500 (previous period: USD 547,300), representing a basic and diluted loss per share of USD 0.012 and USD 0.011 respectively (previous period: basic and diluted loss per share of USD 0.022).